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Introduction: This study aimed to evaluate the cognitive performance of migraine patients
with (MwA) and without aura (MwoA) and investigate the correlation of white matter
hyperintensities (WMHs) and psychological symptoms with their cognitive test scores.
Material andmethods: Hundredmigraine patients aged 20–55 years and 80 healthy volunteers
with similar age, sex, and education level were enrolled. The total Montreal Cognitive
Assessment (MoCA) scores were compared by age, sex, presence of aura, migraine duration,
attack frequency, pain localization, presence and number of WMHs, and the scores of the
Beck Depression Inventory and the Beck Anxiety Inventory (BAI).
Results: Forty-seven (47%) patients had MwA and 53 (53%) had MwoA. The performance of
the MwA patients was signiﬁcantly poorer than that of the MwoA patients and the healthy
subjects on theMoCA scales. In particular, the results revealed lower scores in the subscales
regarding visuospatial/executive functions, naming, memory, attention, and abstraction in
MwA patients than in the MwoA patients. Compared to healthy controls, more number of
migraine patients had WMHs. The presence and number of WMHs had no signiﬁcant
correlation with the MoCA scores of the migraine patients. There was a signiﬁcant correla-
tion of the BAI and BDI scores with the total MoCA scores considering all migraine patients.
Conclusions: This study suggested that MwA may be associated with low cognitive perfor-
mance which was correlated with depression and anxiety but not with WMHs. Further,
longitudinal studies for assessing the relationship betweenWMHs, cognitive functions, and
ablishing the causality are warranted.© 2018 Polish Neumigraine, and for estrological Society. Published by Elsevier Sp. z o.o. All rights reserved.* Corresponding author at: Clinic of Neurology, Bezmialem University, Adnan Menderes Bulvarı (Vatan Cad.) Fatih, 34093 İstanbul, Turkey.
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prevalence in the general population ranges from 5% to 20% [1]. It
is characterized by recurrent throbbing headaches, nausea and/or
vomiting, and arousal sensitivity to stimulants such as light,
sound, andmovement. A signiﬁcant proportion of the population
(up to21%ofwomenand6%ofmen) experiencesmigraineattacks
[1,2]. As the headache progresses, various autonomic, affective,
cognitive, and sensory symptoms may occur [3]. The extent of
these different symptoms suggests that migraine is more than a
headache. It is a complex neurological disorder affectingmultiple
cortical, subcortical, and brainstem regions; therefore, it is clear
that the migraine brain differs from the non-migraine brain [4].
Increased evidence suggests that in many individuals,
migraine is a chronic disease associated with signiﬁcant
comorbidities, including white matter hyperintensities
(WMHs), which are associated with volume changes in the
white and gray matter regions of the brain [5]. The patho-
physiology of WMHs is unknown. Cortical spreading depres-
sion (CSD) is deﬁned as a propagating wave of glial and
neuronal depolarization that occurs during migraine aura [6].
CSD results in partial activation of matrix metalloproteinases,
hypoperfusion of small penetrating arteries, and altered
vascular permeability. This may cause hypoxic brain injury,
manifesting as WMHs on magnetic resonance imaging (MRI)
[6]. Atherosclerosis and increased age may be the main risk
factors for the development ofWMHs but inmigraine patients,
attack frequency, the duration of disease, presence of aura and
possible comorbid disease are also important in the develop-
ment of WMHs [7,8]. Stroke and WMHs are associated with an
increased risk of dementia [9]; therefore, it can be hypothe-
sized that migraine patients may have impaired cognitive
function. Some previous studies have shown a deleterious
effect of migraine on many cognitive skills, including verbal
ability, attention, psychomotor ability, and memory [10,11].
Especially presence of migraine-related aura has been shown
to be associated with cognitive impairment [12,13]. However,
other studies have not shown any effect of migraine on
cognitive skills [14,15]. Discrepancies between these studies
may possibly be attributed to insufﬁcient neuropsychological
assessments. Moreover, to our knowledge, only a few studies
have considered the possible relationship between cognitive
performance and the psychological symptoms or behavioral
disturbances frequently seen in migraine patients [4,16].
This study aimed to evaluate the cognitive status of
migraine patients with and without aura and investigate the
association of WMHs and psychological symptoms with their
cognitive function.2. Material and methods
This prospective case–control study was performed at the
Neurology Clinic between May 2016 and May 2017. Hundred
migraine patients aged 20–55 years and 80 healthy volunteers
with similar age, sex, and education level were enrolled.
The study was approved by local ethics committee. A
detailed, written informed consent form was obtained fromeach subject before initiating the study. The inclusion criterion
for migraine patients was the diagnosis of migraine according
to the International Classiﬁcation of Headache Disorders III
(beta version) (ICHD-III) [17]. Exclusion criteria were as follows:
other ICHD-III diagnosis (e.g., tension type headache, cluster
headache, etc.); history of cerebrovascular disease, cardiovas-
cular disease, diabetes mellitus, arterial hypertension, or
hyperlipidemia; somatic or psychiatric disorders (e.g., major
depression or psychosis according to DSM-5 criteria); smoking
cigarettes or alcohol/substance abuse; current pregnancy,
lactation, or hormonal contraceptive use; use of drugs such
as antiplatelet agents, anticoagulants, statins, or hormonal
drugs; renal, metabolic, inﬂammatory, infectious, or immune
disease; or possible ‘‘symptomaticmigraine’’ in which theMRI
showed disorders such as ischemic infarcts, arteriovenous
malformations, or brain tumors.
For at least 3 days before and after the neuropsychological
tests, all the patients were migraine free and were not taking
rescuemedications to avoid any possible impact related to the
attacks or to the pharmacological treatments. To ensure this,
all patients were interviewed 3 days after the cognitive
assessments.
The control group patients were selected from among the
relatives of the migraine patients, hospital employees, or the
general population. Written consent was obtained from them for
voluntary participation in the study. The inclusion criteria for the
control groupwereas follows: absenceofmigraine, themaximum
frequency of any headache less than 1 episode per month (e.g.,
tension type headache, or any other type of chronic headache)
and the absence of a diagnosed psychiatric disorder (e.g., major
depression or psychosis). Exclusion criteria for the healthy
controls were the same as those for the migraine patients.
Demographic and clinical characteristics such as disease
duration, frequency of migraine attacks (number of migraine
attacks permonth), pain localization, and the presence of aura
were recorded.
2.1. Cognitive assessment
The Montreal Cognitive Assessment (MoCA) [18] was used for
evaluating the cognitive function of themigraine patients and
healthy controls. The MoCA is a 30-point test that assesses
several cognitive domains; it takes 10–15 min to complete.
Mild CI is indicated by a total score <15.5 on the following
subscales: visuospatial/executive functions, naming, memory,
attention, language, abstraction, and orientation [19].
2.2. Assessment of depression and anxiety
Depression and anxiety symptoms were evaluated using the
BDI and the BAI scores, respectively. The Beck depression and
anxiety inventories comprise 21 questions and are scored
between 0 and 63 points. The depression and anxiety cut-off
values were taken as BDI score ≥10 points and BAI score ≥17
points, respectively [20,21].
2.3. White matter hyperintensities
All participants underwent whole-brain MRI using the same
1.5 T MRI scanner (Siemens Verio). The scans included ≥3
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recovery (FLAIR), and sagittal T1-weighted images. The slice
thickness was 5 mm, the gap was 1 mm, and no intravenous
contrast was used.
All MRI scans were reviewed and scored by the same
neuroradiologist who was blinded to the clinical details. The
scans were visually assessed for the presence and features of
WMHs including appearance, number, and distribution.
WMHs were deﬁned as clearly hyperintense areas relative to
the surrounding white matter on both, FLAIR and T2-weighted
images and identiﬁed by simultaneous inspection of both
aligned images.
The number ofWMHswas determined on the FLAIR images
and grouped according to their location and distribution.
Subgroups were delineated according to the distribution of the
WMHs according to the methodology previously described for
multiple sclerosis patients [22]. These subgroups were subcor-
tical, juxtacortical, and periventricular. The locations of the
WMHs were deﬁned as frontal, parietal, temporal, occipital, or
infratentorial. We included focal and punctate hyperintensi-
ties (size < 9 mm) and excluded conﬂuent and large hyper-
intensities (size > 9 mm).
Migraine patients who had WMHs that were detected on
brain MRI were evaluated using laboratory tests for vasculitis
(antinuclear antibody, lupus anticoagulant, anticardiolipin
antibodies, antidouble-stranded DNA autoantibody, as well as
C3 and C4 levels). They also underwent cardiac examination to
rule out patent foramen ovale and atrial septal defect.
2.4. Statistical analysis
The data were transferred into the IBM SPSS Statistics 23
Program and the analyses were completed. When descriptive
statistics (N, %) were used for categorical variables, the
descriptive statistics (mean, standard deviation) were given
for numerical variables. Independent t test was used to
examine the difference between the categorical variables
having two groups; whereas, one-way ANOVA test (one way
analysis of variance) was used for examining the difference
between the categorical variables having more than two
groups. While chi square test was used for examining the
correlation between the two categorical variables, Pearson
Correlation Coefﬁcients were used for examining the correla-
tion between the two numerical variables. In order to
investigate the effect of the independent variables on this
dependent variable, the multiple linear regressions was used.3. Results
Four patients were excluded since they were experienced
migraine attacks during the 3 days following the cognitive
assessments. Demographic and clinical characteristics, cogni-
tive status, as well as depression and anxiety scores of the
patient and control groups are shown in Table 1. No signiﬁcant
difference was detected between the groups in terms of age,
sex, and formal education level (p = 0.4, p = 0.216, and
p = 0.160, respectively).
In the migraine group, 29 patients (29%) were primary
school graduates, 12 (12%) were secondary school graduates,31 were (31%) high-school graduates, and 28 (28%) were
university graduates. In the control group, 12 individuals (15%)
were primary school graduates, 16 (20%) were secondary
school graduates, 30 (37%) were high-school graduates, and 22
(27.5%) were university graduates. The mean education levels
of the migraine patients and healthy subjects were 10  3.9
and 10.7  3.6 years, respectively. Therewas also no difference
between the education levels of MwA and MwoA patients (9.8
 4 and 10.3  3.5 years, respectively, p: 0.230).
Forty-seven (47%) patients had migraine with aura (MwA)
and 53 (53%) had migraine without aura (MwoA). Thirty-two
patients reported headache in the right half of the head, while
24 patients had a headache in the left half of the head. Forty-
four patients reported bilateral, generalized throbbing pain.
3.1. Cognitive assessment
No signiﬁcant differencewas found in the total MoCA scores of
the migraine patients and healthy subjects (p = 0.138). Four
migraine patients were found to havemild CI as per the MoCA
scale (score < 15.5) (Table 1).
The cognitive performance of the MwA patients was
signiﬁcantly poorer than that of the MwoA patients and the
healthy subjects ( p = 0.014 and p = 0.030, respectively). The
mean MoCA scores of the MwA patients, MwoA patients, and
healthy controls were 21.7  5, 24.9  3.5, and 24.4  3.8,
respectively. No signiﬁcant relationship was found between
the total MoCA scores of the MwoA patients and the healthy
controls (p = 0.547).
When we evaluated the MoCA subdomains using linear
regression analysis, presence of aura was found to be
associated with visuospatial/executive functions, naming,
memory, attention, and abstraction domains in migraine
patients (p = 0.003, p = 0.044, p = 0.028, p = 0.001, and p = 0.001,
respectively). When we compared the 3 groups (MwA, MwoA
and the control group) with one-way ANOVA test, the total
MOCA scores of the MwA group was statistically signiﬁcantly
lower ( p < 0.05).
3.2. Analysis of the association between depression,
anxiety and cognitive function
No signiﬁcant difference was detected between the migraine
patients and healthy controls in terms of their BDI and BAI
scores ( p = 0.719, p = 0.836) (Table 1). There was no signiﬁcant
correlation of the BDI scores with the total MoCA scores when
all participants were considered (r: 145, p = 0.052). On the
contrary, a statistically signiﬁcant correlation was found
between the BDI and total MoCA scores in migraine patients
( p = 0.042). The BDI scores were signiﬁcantly correlated to
memory, attention, and abstraction domains (p = 0.002,
p = 0.041, and p = 0.016, respectively).
We found a signiﬁcant correlation of the BAI score with the
total MoCA scores in migraine patients (r: 0.248, p = 0.013).
Cognitive performance pertaining to memory, attention,
language, and abstraction was found to be correlated with
the BAI scores (p = 0.001, p = 0.018, p = 0.002, and p = 0.001,
respectively). The correlations of the BDI and BAI scores with
the total MoCA scores and the MoCA subdomains in migraine
patients are shown in Table 2.
Table 1 – Demographic and clinical characteristics, cognition, depression and anxiety scores of the patient and the control
groups.
Migraine group (n:100) Control group (n:80) p*
Gender (m/f) n (%) 9/91 (9/91) 10/70 (12.5/87.5) 0.4
Mean  SD Mean  SD
Migraine duration (year) 7.4  7.1 –
Attack frequency (per month) 3.6  2.09 –
Presence of aura n (%) 47(47) –
Age (year) 36.7  9.4 34.4  11.02 0.216
BAI score 17.5  12.1 17.1  11.1 0.836
BAI (≥17) n (%) 43(43) 31(38.8) 0.565
BDI score 15.1  10.3 15.3  9.2 0.719
BDI (≥10) n (%) 60(60) 51(63.8) 0.607
MoCA score 23.4  4.5 24.4  3.8 0.138
MoCA (<15.5) n (%) 4(4) 0(0) 0.130
Presence of WMHs n (%) 32(32) 15(18.8) 0.044
Number of WMHs 3.5  4.7 2.5  1.5 0.353
Visuospatial score 4.08  1.02 4.1  0.906 0.568
Naming score 2.64  0.5 2.74  0.522 0.181
Memory score 2.4  1.5 2.5  1.6 0.595
Attention score 4.6  1.3 4.9  1.2 0.167
Language score 2.05  1.03 2.3  0.9 0.075
Abstraction score 1.6  0.59 1.9  0.38 0.032
Orientation score 5.97  0.171 5.96  0.191 0.783
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; MoCA, Montreal Cognitive Assessment; WMHs, white matter hyperintensities.
* p < 0.05.
Table 2 – The association between the MoCA subdomains, patient characteristics, and other evaluated data in migraine
patients.
(p*[2_TD$DIFF]) Visuospatial
functions
Naming Memory Attention Language Orientation Abstraction Total
MoCA scores
Age p: 0.007 p: 0.248 p: 0.001 p: 0.004 p: 0.036 p: 0.585 p: 0.01 p: 0.001
r: 0.267 r: 0.117 r: 0.378 r: 0.285 r: 0.210 r: 0.055 r: 0.289 r: .363
Education level p: 0.001 p: 0.001 p: 0.01 p: 0.01 p: 0.001 p: 0.898 p: 0.001 p: 0.001
r: 0.557 r: 0.368 r: 0.578 r: 0.505 r: 0.449 r: 0.013 r: 0.488 r: 0.677
Pain localization p: 0.362 p: 0.451 p: 0.558 p: 0.022 p: 0.03 p: 0.809 p: 0.44 p: 0.121
r: 0.092 r: 0.076 r: 0.059 r: 0.230 r: 0.218 r: 0.024 r: 0.07 r: 0.273
Attack frequency p: 0.023 p: 0.094 p: 0.046 p: 0.075 p: 0.002 p: 0.770 p: 0.002 p: 0.001
r: 0.293 r: 0.168 r: 0.200 r: 0.179 r: 0.310 r: 0.03 r: 0.310 r: .304
Migraine duration p: 0.139 p: 0.469 p: 0.385 p: 0.653 p: 0.185 p: 0.177 p: 0.032 p: 0.165
r: 0.149 r: 0.073 r: 0.088 r: 0.045 r: 0.134 r: 0.136 r: 0.214 r: .140
BAI p: 0.313 p: 0.135 p: 0.001 p: 0.018 p: 0.002 p: 0.427 p: 0.001 p: 0.013
r: 0.01 r: 0.151 r: 0.342 r: 0.236 r: 0.305 r: 0.08 r: 0.315 r: .248
BDI p: 0.152 p: 0.382 p: 0.002 p: 0.041 p: 0.096 p: 0.083 p: 0.016 p: 0.042
r: 0.144 r: 0.088 r: 0.306 r: 0.205 r: 0.167 r: 0.015 r: 0.238 r: .280
Number of WMHs p: 0.810 p: 0.437 p: 0.934 p: 0.361 p: 0.501 p: 0.862 p: 0.810 p: 0.597
r: 0.04 r: 0.130 r: 0.014 r: 0.153 r: 0.113 r: 0.029 r: 0.04 r: .089
MoCA, Montreal Cognitive Assessment; WMHs, white matter hyperintensities; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory.
*
[1_TD$DIFF]p < 0.05, with Pearson correlation coefﬁcients.
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Compared to healthy controls, a signiﬁcantly higher number of
migraine patients had WMHs ( p = 0.044) (Table 1). No signiﬁ-
cant relationship was found in terms of the number of WMHs
per subject (p = 0.353). WMH was detected in 12 (25.5%) of the
MwA patients and in 20 (37.7%) of the MwoA patients. The
WMHs in themigraine and control groups were detectedmost
frequently in the frontal lobe and least frequently in the
occipital lobe. In the 100 migraine patients, we foundperiventricular WMHs in 2 (2%), juxtacortical WMHs in 7
(7%: frontal 4%, parietal 1%, frontal and parietal 2%), and
subcorticalWMHs in 32 patients (32%: frontal 13%, parietal 3%,
temporal 2%, occipital 1%, multiple localization 13%). The
presence and number of WMHs was not signiﬁcantly correlat-
edwith the totalMoCA scores norwith theMoCA sub-domains
of the migraine patients (Table 2). There was no signiﬁcant
difference betweenWMHs (+) andWMHs () migraine patients
in terms of attack frequency, disease duration and total MoCA
scores ( p = 0.683, p = 0.420, and p = 0.204, respectively).
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We evaluated the association of total MoCA scores with other
parameters in migraine patients as one group (without
differentiation between those with and without aura) to
maintain the statistical clarity of the study.
Attack frequency was signiﬁcantly correlated to the MoCA
scores in migraine patients but migraine duration was not
(Table 2). Additionally, pain localization was not correlated to
the total MoCA scores in MwA patients ( p: 0.095).
Finally, we evaluated the MoCA subdomains, patient
characteristics, and other evaluated data using linear regres-
sion analysis in migraine patients. BAI was associated with
memory, attention, language and orientation domains
(p = 0.05, p = 0.011, p = 0.032 and p = 0.001, respectively) and
BDIwas only associatedwith orientation (p = 0.018).When the
total MoCA scores were evaluated with linear regression
analysis, no signiﬁcant differences were detected with the
patient characteristics, and other evaluated data (p > 0.05).
4. DiscussionThe present study revealed that MwA patients had signiﬁ-
cantly lower total MoCA scores than MwoA patients and
healthy controls. In particular, our results revealed lower
scores in the subscales regarding visuospatial/executive
functions, naming, memory, attention, and abstraction in
MwA patients than in the MwoA patients. Regarding the
psychological assessment, the migraine patients and healthy
subjects reported similar scores for depression (BDI) and
anxiety (BAI). In patients with migraine, a statistically
signiﬁcant correlation was found between the BDI and BAI
scores and total MoCA scores. Compared to healthy controls,
more number of migraine patients had WMHs. Cognitive
scores in migraine patients were not associated with the
presence and number of WMHs.
The prevalence of WMHs in migraine patients ranges from
14% to 59% [8]. Although themechanisms and causes ofWMHs
are still debatable and many theories have been proposed,
clear data showing the pathophysiological correlations are still
lacking. Some peptides (e.g., substance P, calcitonin gene-
related peptide, and neurokinin A) are released from the
perivascular trigeminal regions after the activation of the brain
tissue; this causes dilation and inﬂammation of the extra-
parenchymal vessels. This could lead to cerebral ischemia
caused by the effects on the cerebral blood ﬂow [6]. On the
contrary, inﬂammatory arteriopathy of the cranial vessels is
associated with migraine attacks [23].
A recent meta-analysis showed an association between
WMHs and MwA; however, this association was not seen in
MwoA patients [5]. Another meta-analysis, carried out by
Schurks et al. [24], included 25 heterogeneous studies and
showed that theWMH burdenwas higher inmigraine patients
and was correlated to each type of migraine, with the MwA
patients having the highest number of WMHs. In keeping with
previous ﬁndings, the presence of WMHs was signiﬁcantly
higher in migraine patients than in the healthy controls in our
study. The WMH burden in MwoA patients was greater than
that in MwA patients. Several issues regarding these WMHs,including whether they accumulate over time in repeat MRI
assessments, whether hyperintensities constitute a risk for
stroke, and whether they have an impact on cognitive
performance in migraine patients, remain debatable. Mi-
graine-related WMHs need to be distinguished from white
matter lesions that are related to cerebral small-vessel disease
and silent brain infarcts, both of which are associated with a
risk of future stroke, cognitive decline, and dementia [25].
Therefore, we excluded conﬂuent and large hyperintensities
similar to a previous study [23].
Studies on the relationship betweenmigraine and cognitive
performance show contradictory results. Some cross-sectional
studies have not found any differences between migraine
patients and healthy controls [15,16], while others have shown
evidence of cognitive decline among migraine patients
compared to that in controls [12,26]. Interestingly, some
studies have reported that migraineurs have shown less
cognitive decline compared to nonmigraineurs [27,28]. Dis-
crepancies between these studies may possibly be attributed
to the differences in patient characteristics (some studies
enrolled both, patients with and without aura), number of
patients, or the differences in the neuropsychological assess-
ments performed. In our study, no signiﬁcant differences were
found between the results of the cognitive abilities of the
migraine patients and healthy controls. TheMwApatients had
signiﬁcantly lower total MoCA scores than healthy subjects,
while the cognitive performance of the MwoA patients and
healthy controls was found to be comparable. In particular, in
consensuswith the ﬁndings of previous studies, we found that
in comparison to the MwoA patients, the MwA patients
achieved lower scores in the subscales assessing visuospatial/
executive functions, naming, verbal memory, attention, and
abstraction [12,13,29]. These ﬁndings may be compatible with
the hypothesis that subtle alterations in the information
processingmechanisms could be present in the early stages of
migraine [13]. The decline in verbal memory might be
attributed to the defective strategic and organizational aspects
of learning [29], also in consideration of the lower executive
functions and attention subdomains.
In our study, the presence and number of WMHs were not
correlated to cognitive functioning in migraine patients.
Similarly, in the EVA study that used the MRI data of 775
participants, the presence of WMHs was not found to be
associated with the development of migraine and cognitive
deﬁcits using most cognitive tests [30].
Previous studies assessed the cognitive functions of
migraine patients and found that the attack frequency and
disease duration were not related to cognitive decline [13,31].
We found a signiﬁcant relationship between the attack
frequency, migraine duration, and MoCA scores, which may
be attributed to the different sample sizes or cognitive scales.
Regarding the psychological assessment, there were no
signiﬁcant differences in the severity of depression and
anxiety in migraine patients compared to that in healthy
subjects. We found a statistically signiﬁcant correlation
between depression, anxiety, and total MoCA scores in
migraine patients. Both, depression and anxiety have been
shown to be early predictors of future cognitive decline in
previous studies [32,33]. However, another study has reported
that anxiety and depression in elderly people is not associated
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study including MwoA patients revealed no correlation
between neuropsychiatric symptoms and cognitive tests [1].
The divergence among the studies might be due to the
difference in the sample sizes, inclusion and exclusion criteria,
and tools used for assessing the neuropsychiatric proﬁle and
cognition.
We aimed to evaluate the general cognitive functioning of
migraine patients, for which we used a relatively recent tool
(the MoCA test). The MoCA has been developed for assessing
several cognitive subdomains that are often overlooked by
more common screening tools. Nevertheless, our study
requires a complete and speciﬁc battery of anyway, especially
in relation to the various subdomains and neuropsychiatric
symptoms such as anxiety and depression. The cut off score
derived for theMoCA test was consistent with Italian norms in
this study [19]. However, some research has suggested that a
higher normative data would yield more accurate results [35].
All subjects were scanned using the same MRI scanner at a
single center. However, anMRI scannerwith a highermagnetic
ﬁeld and higher sensitivity than the one used in our study
would have been more sensitive in detecting the WMHs. The
sample size was small, especially, the number of patients with
WMHs, as determined using MRI was lower than required for
drawing meaningful and representative results. Assessment
of WMHs with validated methods would be more convenient
(e.g., Fazekas score, Scheltens' score [36,37]). Additionally,
contrary to the previous studies [38,39], a higher number of
patients had MwA in our study and we did not evaluate the
subtypes ofMwA.More accurate results can be obtainedwith a
larger sample size and longer follow-up periods. Finally, our
study was cross-sectional indicating an association rather
than a causal relationship. We did not evaluate the changes in
the cognitive functions over time although dementia is usually
determined by observing these changes. Longitudinal studies
are needed in future to better understand the mechanisms of
cognitive deﬁcits in this population.
5. ConclusionsThis study suggested that the effects of migraine are not
limited to headaches. Especially migraine with aura may be
associated with some comorbidities, including cognitive
decline. Whether migraine patients with WMHs are at greater
risk of cognitive decline than those without WMHs is under
debate and needs to be prospectively evaluated. Thus, these
results also highlighted the importance of carefully assessing
the cognitive performance using a screening tool that is as
sensitive as theMoCA test in detecting visuospatial/executive,
attention, and memory dysfunctions. Further, longitudinal
studies for assessing the relationship between WMHs, cogni-
tive decline, and migraine, and for establishing the causality
are warranted.
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